http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1681752

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 606
issn 1525-4135
issueIdentifier 5
pageRange 598-606
publicationName Journal of acquired immune deficiency syndromes (1999)
startingPage 598
bibliographicCitation Lamarca A, Clumeck N, Plettenberg A, Domingo P, Fu K, Craig C, Zhao H, Watson M, Gordon D, Scott T. Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):598–606. doi: 10.1097/01.qai.0000214821.33905.5c. PMID: 16652033.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16acbd378d14da2235c4442a2fc378e8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e87db8b1612535e29368228cbe8e8647
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dcb6dfccc5a83a8ce8270f0e35c42a41
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f785ad0f42200f6c708977098ad2749e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b0bd8644527a3b549722475704b0c983
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_505ce0657c910d546aa33b09168662e7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e7a040ba6550a46817571d4f70d69b8f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_638734609f171d2fc4a9604e612acb90
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3276-9925
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_557398f7f1cd1df0233e0fe55be9bc1e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db03cd76054a0a32a1b3bd0a1b6c6e64
date 2006-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1097/01.qai.0000214821.33905.5c
https://pubmed.ncbi.nlm.nih.gov/16652033
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21821
https://portal.issn.org/resource/ISSN/1525-4135
language English
source https://pubmed.ncbi.nlm.nih.gov/
title Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study)
discusses http://id.nlm.nih.gov/mesh/M0023387
http://id.nlm.nih.gov/mesh/M0028839
http://id.nlm.nih.gov/mesh/M0028682
http://id.nlm.nih.gov/mesh/M0277557
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D019380Q000627
http://id.nlm.nih.gov/mesh/D015658Q000188
http://id.nlm.nih.gov/mesh/D015224Q000627
http://id.nlm.nih.gov/mesh/D019259Q000627
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D004334
http://id.nlm.nih.gov/mesh/D015497
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D004359
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D019380Q000008
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D015224Q000008
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D012449
http://id.nlm.nih.gov/mesh/D019259Q000008
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9765
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5273759
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID464205
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60825
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441300
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_0943bfb20a0e8ebccd479b74c7b652df
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_89d708279e197fec68596fc46bc48c90

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129233080
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128324017
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128575040

Total number of triples: 58.